

Measles – Historical Perspective on Disease Impact and Vaccine Development

**Robert L. Atmar, M.D.
Baylor College of Medicine**

Disclosures


- **Nothing to disclose**

Measles - History


- **Recognized as early as 7th century by Al Yehudi**
- **Rhazes described as distinct from smallpox in 10th century**
- **1846 Faroe Island outbreak – characteristics described by Danish physician Peter Panum**
- **1911 – Goldberger and Anderson recognized as virus (filterable agent)**
- **1954 – Enders and Peebles grew the virus in human and monkey kidney cell lines**

Rubeola – the Virus

- **Single-stranded RNA virus in the *Paramyxoviridae* family, genus *Morbillivirus***
- **Eight viral proteins**
- **24 genotypes (A, B1-B3, C1-C2, D1-D11, E, F, G1-G3, H1-H2), but only a few commonly circulating globally**
- **One serotype**




Global Distribution of Measles Virus Genotypes by WHO Region: 2019-2023



NOTE: D8 – 9171 (Ontario lineage) not common


Measles - Disease

- Incubation period – 10-14 days (range 7-21 days)
- Prodrome – fever, malaise, cough, coryza, conjunctivitis (3 C's)
- Rash
 - Enanthem – Koplik's spots 2 days before skin rash and 1-2 days after
 - Exanthem – maculopapular; head → trunk → extremities; onset 2-4 days after prodrome onset and can last 4-8 days
- Transmissibility – greatest in 4 days before and after rash onset



Measles - Complications

- **Respiratory – viral or *bacterial***
 - Pneumonia (most common cause of death globally)
 - Otitis media – in ~10% of children
- **Diarrhea (2nd most common cause of death globally)**
- **Blindness (due to corneal scarring in areas with vitamin A deficiency)**
- **CNS**
 - Post-infectious encephalitis (1 per 1000-2000 cases)
 - SSPE – 1 per 10K-100K cases (years later)
- **Death – CFR 3-6% in some countries (1-3/1000 in US)**




Chest 1993;103:1625

Measles – Other Clinical

- **Pregnant women**
 - Prematurity, spontaneous abortion (not congenital abnormalities)
 - ? Increased pneumonia
- **Immunocompromised**
 - May have pneumonia without rash
 - Increased complications (pneumonia, hospitalizations, encephalitis)
 - Increased mortality
- **Hepatitis and sinusitis in adults as additional complications**


Deaths due to measles by region, 1980 to 2021

Estimated annual number of deaths due to measles¹.



Data source: IHME, Global Burden of Disease (2024)

Reported Cases of Measles in US 1938-2025



Measles Vaccines

- **Inactivated (formalin-inactivated, alum-precipitated)**
 - 1963-1967
 - Short term immunity
 - Atypical measles syndrome – rash palms/soles spreads centripetally; erythematous → maculopapular → vesicular, petechial or purpuric; lung involvement common; altered immune response and immune complex formation

Atypical measles rash


A: m-p and purpuric rash

B: purpuric rash of palm



Measles Vaccines


- **Live-attenuated (Edmonston B) – Genotype A**
 - 1967-1975
 - Fever, rash common
 - Administered with Ig → modified measles syndrome; some signs can be absent




Measles Vaccines

- **Live-attenuated – further attenuated through serial passage; fever (≥ 103 F in 5-15%)**
 - **Moraten (Merck): 1968 – present**
 - **Schwarz (GSK): 2022 – present**
- **Part of MMR: 1971 – present**
- **Part of MMRV: 2005 – present**


Reported Cases of Measles in US 1938-2025




Measles Vaccine First Dose Coverage by Age Group – US, 1964-1999




Reported Measles Cases in US by Age and Vaccination Status – 1985-1988



Reported Cases of Measles in US 1938-2025



Reported Cases of Measles in US 1938-2025




10 Lessons Learned in Measles Prevention/Elimination


- Requires high vax rates by age 2 years
- School immunization requirements ensure high rates
- A 2nd vax dose improves population immunity
- School immunization requirements can ensure 2nd dose administered
- Coverage assessment crucial
- Measles surveillance critical
- Lab back-up needed to confirm diagnosis
- Tracking genotypes critical for tracking circulation (endemicity?)
- International introduction will continue after elimination
- Collaboration with other countries needed to reduce introduction

MMR Vaccine Coverage For Kindergarteners Has Decreased


■ < 90% (16 states) ■ 90% - 94.9% (23 states including DC) ■ ≥ 95% (10 states)



Reported Cases of Measles in US 1938-2025



Modeling of Measles Re-Emergence at Current Vaccination Rates in US



25-year period – current vax rates


- **851,300 cases**
- **170,200 hospitalizations**
- **2550 deaths**
- **851 with post-neurological sequelae**

Loss of Elimination Status in US May Be Imminent

- Sustained circulation of D8 (mostly DSID 9171) virus in US since January 20, 2025 (beginning of West Texas outbreak) – last TX case 7/1/25, 762 total linked to outbreak
- Cases in New Mexico (100 cases from 2/14/25-8/14/25) epidemiologically linked to W Texas
- Outbreak in Arizona (205 cases Aug to present)/Utah (156 cases total) continues; DSID 9171, but also found in Mexico and Canada (in Mennonite communities)
- Outbreak in South Carolina continues (176 cases in outbreak from Sep to present)

Weekly measles cases by rash onset date

2023–2025* (as of December 30, 2025)



https://www.cdc.gov/measles/data-research/index.html#cdc_data_surveillance_section_10-measles-cases-in-2025

Summary

- **Measles is a vaccine-preventable illness that can cause severe disease and mortality**
- **Measles vaccination eliminated endemic transmission in the US in 2000, although repeated introduction from international locations continued to occur**
- **Decreased vaccine uptake has allowed reintroduction of measles and large outbreaks in unvaccinated groups; further decreases in coverage will lead to more cases and greater impact on the population**